Physician profile
Barry Braver
NPI 1275592412
$2,227.75
in general payments reported to CMS, 2019-2025
27 companies · $366 in 2025
The $366 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.14 · 2020: $103 · 2021: $152 · 2022: $245 · 2023: $564 · 2024: $739 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.35 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $212.93 | 2020-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.85 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $131.33 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $130.09 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $120.39 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $100.78 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $91.04 | 2021-2025 | Bexsero, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $88.26 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Genzyme Corporation | $88.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $81.30 | 2020-2024 | |
| Axsome Therapeutics, INC. | $41.62 | 2022-2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $39.38 | 2021 | |
| Lilly USA, LLC | $31.54 | 2020 | |
| Abbott Laboratories | $30.70 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $30.32 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.90 | 2021 | |
| Genentech USA, INC. | $27.88 | 2020-2021 | |
| Shire North American Group INC | $19.98 | 2019 | |
| Amgen INC. | $18.50 | 2025 | Otezla, Repatha |
| Scynexis, INC. | $17.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.52 | 2024 | Voquezna |
| Kaleo, INC. | $14.32 | 2023 | Auvi-Q |
| Phadia US INC. | $13.63 | 2021 | |
| Dexcom, INC. | $13.22 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.97 | 2022 | |
| Redhill Biopharma INC. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Braver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.